On September 30, 2025, Enanta Pharmaceuticals, Inc. (“Enanta”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 6,500,000 shares of Enanta’s common stock, par value $0.01 per share (the “Common Stock”). The price to the public in the offering was $10.00 per share. In addition, Enanta granted the Underwriters an option, exercisable for 30 days, to purchase up to 975,000 additional shares of Common Stock at the public offering price, less the underwriting discounts and commissions.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”